Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hong Kong Fund Oasis Sues Kobayashi Execs over Beni-Koji Scandal
April 8, 2025
- Japan Ethical Drug Sales Down 5.1% in February: Crecon
April 8, 2025
- Santen’s Glaucoma Drug Tapcom Snags China Approval
April 7, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Struggling Sumitomo Extends Pay Cuts for Board Directors
April 7, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer in Europe
April 7, 2025
- Keytruda Stays Atop Japan Drug Ranking for 18 Months Straight: Encise
April 7, 2025
- Quviviq Tops Sales Rep Call Ranking for GPs in February: Intage
April 4, 2025
- Merck Biopharma to Develop PharmaMar’s SCLC Drug in Japan
April 4, 2025
- Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Trump Tariffs, FDA Layoffs: CEO
April 3, 2025
- Alper Alptekin Becomes Japan President of Organon
April 2, 2025
- Sumitomo Pharma to Offload Asian Biz to Trader Marubeni
April 2, 2025
- Xocova’s US Rolling Submission Starts for COVID Post-Exposure Prophylaxis
April 2, 2025
- Shoichiro Ogawa to Lead Sun Pharma Japan
April 2, 2025
- FunPep Inks Research Pact with French Public Institute on Antibody-Inducing Peptides
April 2, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…